BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Nov 22, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

CD34+ stem cell therapy: Phase IIa data

Researchers at Northwestern University's Feinberg School of Medicine reported data from a double-blind, U.S. Phase IIa trial in 28 patients with late-stage peripheral arterial disease (PAD) and CLI showing that Baxter's autologous hematopoetic CD34+ stem cells injected into 8 locations in the ischemic limb...

Read the full 199 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >